Share this article
TSX Venture: QPT
EDMONTON, AB, June 1, 2021 /PRNewswire/ - Quest PharmaTech Inc. (TSXV: QPT) ( Quest or the Company ) announces that clinical investigators working with OncoQuest Pharmaceuticals, Inc. ( OQP ) lead clinical candidate oregovomab, will be making two presentations as part of the American Society of Clinical Oncology (ASCO) conference proceedings. OQP acquired oregovomab from OncoQuest Inc., one of the equity investee companies (45%) of Quest PharmaTech Inc.
The first presentation by Dr. Angeles Alvarez Secord, Principal Investigator and Associate Director of Clinical Research at Duke Cancer Institute of Duke University will update the research community on progress with the ongoing FLORA 5 phase III clinical study of front-line carboplatin-paclitaxel-oregovomab chemotherapy. This double blind and placebo con